Rythmodan-La

Rythmodan-La Brand names, Rythmodan-La Analogs

Rythmodan-La Brand Names Mixture

No information avaliable

Rythmodan-La Chemical_Formula

C₂₁H₂₉N₃O

Rythmodan-La RX_link

http://www.rxlist.com/cgi/generic2/disopyr.htm

Rythmodan-La fda sheet

Rythmodan-La msds (material safety sheet)

Rythmodan-La Synthesis Reference

No information avaliable

Rythmodan-La Molecular Weight

339.475 g/mol

Rythmodan-La Melting Point

94.5-95 ^oC

Rythmodan-La H₂O Solubility

44.9 mg/L

Rythmodan-La State

Solid

Rythmodan-La LogP

3.972

Rythmodan-La Dosage Forms

Capsule; Tablet (extended-release)

Rythmodan-La Indication

For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias.

Rythmodan-La Pharmacology

Disopyramide is an antiarrhythmic drug indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia that are life-threatening. In man, Disopyramide at therapeutic plasma levels shortens the sinus node recovery time, lengthens the effective refractory period of the atrium, and has a minimal effect on the effective refractory period of the AV node. Little effect has been shown on AV-nodal and His-Purkinje conduction times or QRS duration. However, prolongation of conduction in accessory pathways occurs.

Rythmodan-La Absorption

Nearly complete

Rythmodan-La side effects and Toxicity

LD₅₀=580 mg/kg in rats

Rythmodan-La Patient Information